Synthesis of a CCR3 Antagonist

T.-Y. Yue; D. D. McLeod; K. B. Albertson; S. R. Beck; J. Deerberg; J. M. Fortunak; W. A. Nugent; L. A. Radesca; L. Tang; C. D. Xiang

doi:10.1055/s-2006-942046

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synfacts 2006(9): 0863-0863
DOI: 10.1055/s-2006-942046

Synthesis of Natural Products and Potential Drugs

Synthesis of a CCR3 Antagonist

Contributor(s): Philip Kocienski
T.-Y. Yue*, D. D. McLeod, K. B. Albertson, S. R. Beck, J. Deerberg, J. M. Fortunak, W. A. Nugent, L. A. Radesca, L. Tang, C. D. Xiang
Bristol-Myers Squibb, New Brunswick, USA

Further Information

Publication History

Publication Date:
23 August 2006 (online)

Permissions and Reprints

Significance

The CCR3 antagonist M is a potential treatment for asthma and allergic rhinitis. The synthesis depicted provided 20 kg of the target. Key steps include the asymmetric hydrogenation of B to C and the quinidine-mediated desymmetrization of the meso-anhydride E.